Literature DB >> 22552699

Molecular virology of the henipaviruses.

Paul A Rota1, Michael K Lo.   

Abstract

Nipah (NiV) and Hendra (HeV) viruses comprise the genus Henipavirus and are highly pathogenic paramyxoviruses, which cause fatal encephalitis and respiratory disease in humans. Since their respective initial outbreaks in 1998 and 1994, they have continued to cause sporadic outbreaks resulting in fatal disease. Due to their designation as Biosafety Level 4 pathogens, the level of containment required to work with live henipaviruses is available only to select laboratories around the world. This chapter provides an overview of the molecular virology of NiV and HeV including comparisons to other, well-characterized paramyxoviruses. This chapter also describes the sequence diversity present among the henipaviruses.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552699     DOI: 10.1007/82_2012_211

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  12 in total

1.  Evaluation of luciferase and GFP-expressing Nipah viruses for rapid quantitative antiviral screening.

Authors:  Michael K Lo; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2014-03-27       Impact factor: 5.970

2.  4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency.

Authors:  Anne L Hotard; Biao He; Stuart T Nichol; Christina F Spiropoulou; Michael K Lo
Journal:  Antiviral Res       Date:  2017-06-17       Impact factor: 5.970

3.  Structure and stabilization of the Hendra virus F glycoprotein in its prefusion form.

Authors:  Joyce J W Wong; Reay G Paterson; Robert A Lamb; Theodore S Jardetzky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

Review 4.  Henipavirus infection of the central nervous system.

Authors:  Brian E Dawes; Alexander N Freiberg
Journal:  Pathog Dis       Date:  2019-03-01       Impact factor: 3.166

5.  Rhabdovirus-based vaccine platforms against henipaviruses.

Authors:  Drishya Kurup; Christoph Wirblich; Heinz Feldmann; Andrea Marzi; Matthias J Schnell
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

Review 6.  Type I and Type II Interferon Antagonism Strategies Used by Paramyxoviridae: Previous and New Discoveries, in Comparison.

Authors:  Giuseppe Pisanelli; Ugo Pagnini; Giuseppe Iovane; Adolfo García-Sastre
Journal:  Viruses       Date:  2022-05-21       Impact factor: 5.818

7.  Protection against henipaviruses in swine requires both, cell-mediated and humoral immune response.

Authors:  Brad S Pickering; John M Hardham; Greg Smith; Eva T Weingartl; Paul J Dominowski; Dennis L Foss; Duncan Mwangi; Christopher C Broder; James A Roth; Hana M Weingartl
Journal:  Vaccine       Date:  2016-08-17       Impact factor: 3.641

8.  Molecular characterization of Nipah virus from Pteropus hypomelanus in Southern Thailand.

Authors:  Supaporn Wacharapluesadee; Panumas Samseeneam; Mana Phermpool; Thongchai Kaewpom; Apaporn Rodpan; Pattarapol Maneeorn; Phimchanok Srongmongkol; Budsabong Kanchanasaka; Thiravat Hemachudha
Journal:  Virol J       Date:  2016-03-25       Impact factor: 4.099

9.  Indirect ELISA based on Hendra and Nipah virus proteins for the detection of henipavirus specific antibodies in pigs.

Authors:  Kerstin Fischer; Sandra Diederich; Greg Smith; Sven Reiche; Vinicius Pinho Dos Reis; Eileen Stroh; Martin H Groschup; Hana M Weingartl; Anne Balkema-Buschmann
Journal:  PLoS One       Date:  2018-04-30       Impact factor: 3.240

10.  ANP32B is a nuclear target of henipavirus M proteins.

Authors:  Anja Bauer; Sebastian Neumann; Axel Karger; Ann-Kristin Henning; Andrea Maisner; Boris Lamp; Erik Dietzel; Linda Kwasnitschka; Anne Balkema-Buschmann; Günther M Keil; Stefan Finke
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.